106 results on '"Esterle, L."'
Search Results
2. Depressive symptoms after hepatitis C cure and socio-behavioral correlates in aging people living with HIV (ANRS CO13 HEPAVIH)
- Author
-
Salmon, D., Usubillaga, R., Sogni, P., Terris, B., Tremeaux, P., Katlama, C., Valantin, M.A., Stitou, H., Simon, A., Cacoub, P., Nafissa, S., Benhamou, Y., Charlotte, F., Fourati, Virologie: S., Poizot-Martin, I., Zaegel, O., Laroche, H., Tamalet, C., Pialoux, G., Chas, J., Callard, P., Bendjaballah, F., Amiel, C., Le Pendeven, C., Marchou, B., Alric, L., Barange, K., Metivier, S., Selves, J., Larroquette, F., Rosenthal, E., Infectiologie, Naqvi, A., Rio, V., Haudebourg, J., Saint-Paul, M.C., Monte, A. De, Giordanengo, V., Partouche, C., Bouchaud, O., Martin, A., Ziol, M., Baazia, Y., Iwaka-Bande, V., Gerber, A., Uzan, M., Bicart-See, A., Garipuy, D., Ferro-Collados, M.J., Virologie, Nicot, F., Gervais, A., Yazdanpanah, Y., Adle-Biassette, H., Alexandre, G., Peytavin, G., Lascoux-Combe, C., Molina, J.M., Bertheau, P., Chaix, M.L., Delaugerre, C., Maylin, S., Lacombe, K., Bottero, J., Krause, J., Girard, P.M., Wendum, D., Cervera, P., Adam, J., Viala, C., Vittecocq, D., Goujard, C., Quertainmont, Y., Teicher, E., Pallier, C., Lortholary, O., Duvivier, C., Rouzaud, C., Lourenco, J., Touam, F., Louisin, C., Avettand-Fenoel, V., Gardiennet, E., Mélard, A., Neau, D., Ochoa, A., Blanchard, E., Castet-Lafarie, S., Cazanave, C., Malvy, D., Dupon, M., Dutronc, H., Dauchy, F., Lacaze-Buzy, L., Desclaux, A., Bioulac-Sage, P., Trimoulet, P., Reigadas, S., Morlat, P., Lacoste, D., Bonnet, F., Bernard, N., Hessamfar, M., J, Paccalin, F., Martell, C., Pertusa, M.C., Vandenhende, M., Mercié, P., Pistone, T., Receveur, M.C., Méchain, M., Duffau, P., Rivoisy, C., Faure, I., Caldato, S., Bellecave, P., Tumiotto, C., Pellegrin, J.L., Viallard, J.F., Lazzaro, E., Greib, C., Zucman, D., Majerholc, C., Brollo, M., Farfour, E., Boué, F., Devoto, J. Polo, Kansau, I., Chambrin, V., Pignon, C., Berroukeche, L., Fior, R., Martinez, V., Abgrall, S., Favier, M., Deback, C., Lévy, Y., Dominguez, S., Lelièvre, J.D., Lascaux, A.S., Melica, G., Billaud, E., Raffi, F., Allavena, C., Reliquet, V., Boutoille, D., Biron, C., Lefebvre, M., Hall, N., Bouchez, S., Rodallec, A., Le Guen, L., Hemon, C., Miailhes, P., Peyramond, D., Chidiac, C., Ader, F., Biron, F., Boibieux, A., Cotte, L., Ferry, T., Perpoint, T., Koffi, J., Zoulim, F., Bailly, F., Lack, P., Maynard, M., Radenne, S., Amiri, M., Valour, F., Augustin-Normand, C., Scholtes, C., Le-Thi, T.T., Piroth, L., Chavanet, P., Duong Van Huyen, M., Buisson, M., Waldner-Combernoux, A., Mahy, S., Salmon Rousseau, A., Martins, C., Aumaître, H., Galim, S., Bani-Sadr, F., Lambert, D., Nguyen, Y., Berger, J.L., Hentzien, M., Brodard, V., Rey, D., Partisani, M., Batard, M.L., Cheneau, C., Priester, M., Bernard-Henry, C., de Mautort, E., Fischer, P., Gantner, P., Fafi-Kremer, S., Roustant, F., Platterier, P., Kmiec, I., Traore, L., Lepuil, S., Parlier, S., Sicart-Payssan, V., Bedel, E., Anriamiandrisoa, S., Pomes, C., Mole, M., Bolliot, C., Catalan, P., Mebarki, M., Adda-Lievin, A., Thilbaut, P., Ousidhoum, Y., Makhoukhi, F.Z., Braik, O., Bayoud, R., Gatey, C., Pietri, M.P., Le Baut, V., Ben Rayana, R., Bornarel, D., Chesnel, C., Beniken, D., Pauchard, M., Akel, S., Lions, C., Ivanova, A., Ritleg, A.-S., Debreux, C., Chalal, L., Zelie, J., Hue, H., Soria, A., Cavellec, M., Breau, S., Joulie, A., Fisher, P., Gohier, S., Croisier-Bertin, D., Ogoudjobi, S., Brochier, C., Thoirain-Galvan, V., Le Cam, M., Wittkop, L., Esterle, L., Izopet, J., Serfaty, L., Paradis, V., Spire, B., Carrieri, P., Zaegel-Faucher, O., Meyer, L., Boufassa, F., Autran, B., Roque, A.M., Solas, C., Fontaine, H., Costagliola, D., Petrov-Sanchez, V., Levier, A., P. Carrieri, Chalouni, M., Conte, V., Dequae-Merchadou, L., Desvallées, M., Gilbert, C., Gillet, S., Guillochon, Q., Khan, C., Knight, R., Marcellin, F., Michel, L., Mora, M., Protopopescu, C., Roux, P., Barré, T., Ramier, C., Sow, A., Di Beo, V., Bureau, M., Marcellin, Fabienne, Brégigeon-Ronot, Sylvie, Ramier, Clémence, Protopopescu, Camelia, Gilbert, Camille, Di Beo, Vincent, Duvivier, Claudine, Bureau-Stoltmann, Morgane, Rosenthal, Eric, Wittkop, Linda, Salmon-Céron, Dominique, Carrieri, Patrizia, Sogni, Philippe, and Barré, Tangui
- Published
- 2023
- Full Text
- View/download PDF
3. Daily cannabis and reduced risk of steatosis in human immunodeficiency virus and hepatitis C virus‐co‐infected patients (ANRS CO13‐HEPAVIH)
- Author
-
Nordmann, S., Vilotitch, A., Roux, P., Esterle, L., Spire, B., Marcellin, F., Salmon‐Ceron, D., Dabis, F., Chas, J., Rey, D., Wittkop, L., Sogni, P., Carrieri, P., Salmon, D, Trimoulet, P, Izopet, J, Serfaty, L, Paradis, V, Valantin, M.A., Pialoux, G, Poizot‐Martin, I, Barange, K, Naqvi, A, Rosenthal, E, Bicart‐See, A, Bouchaud, O, Gervais, A, Lascoux‐Combe, C, Goujard, C, Lacombe, K, Duvivier, C, Vittecoq, D, Neau, D, Morlat, P, Bani‐Sadr, F, Meyer, L, Boufassa, F, Dominguez, S, Autran, B, Roque, A.M., Solas, C, Fontaine, H, Costagliola, D, Piroth, L, Simon, A, Zucman, D, Boué, F, Miailhes, P, Billaud, E, Aumaître, H, Couffin‐Cadiergues, S, Marchand, L, Salmon, D, Alagna, L, Sogni, P, Terris, B, Krivine, A, Katlama, C, Valantin, M.A., Stitou, H, Benhamou, Y, Charlotte, F, Fourati, S, Simon, A, Cacoub, P, Nafissa, S, Poizot‐Martin, I, Zaegel, O, Porcher, M, Tamalet, C, Pialoux, G, Chas, J, Slama, L, Callard, P, Bendjaballah, F, Le Pendeven, C, Marchou, B, Alric, L, Barange, K, Metivier, S, Selves, J, Larroquette, F, Rosenthal, E, Haudebourg, J, Saint‐Paul, M.C., Partouche, C, Bouchaud, O, Ziol, M, Baazia, Y, Uzan, M, Bicart‐See, A, Garipuy, D, Ferro‐Collados, M.J, Selves, J, Nicot, F, Gervais, A, Yazdanpanah, Y, Adle‐Biassette, H, Alexandre, G, Lascoux‐Combe, C, Molina, J.M, Bertheau, P, Duclos, J, Palmer, P, Lacombe, K, Campa, P, Girard, P.M, Wendum, D, Cervera, P, Adam, J, Viala, C, Goujard, C, Pallier, C, Vittecoq, D, Lortholary, O, Duvivier, C, Shoai‐Tehrani, M, Mélard, A, Neau, D, Ochoa, A, Blanchard, E, Castet‐Lafarie, S, Cazanave, C, Malvy, D, Dupon, M, Dutronc, H, Dauchy, F, Lacaze‐Buzy, L, Bioulac‐Sage, P, Trimoulet, P, Reigadas, S, Morlat, P, Lacoste, D, Bonnet, F, Bernard, N, Bonarek Hessamfar, M, Roger‐Schmeltz, J, Gellie, P, Thibaut, P, Paccalin, F, Martell, C, Carmen Pertusa, M, Vandenhende, M, Mercier, P, Malvy, D, Pistone, T, Receveur, M.C, Caldato, S, Bioulac‐Sage, P, Trimoulet, P, Reigadas, S, Pellegrin, J.L, Viallard, J.F, Lazzaro, E, Greib, C, Bioulac‐Sage, P, Trimoulet, P, Reigadas, S, Zucman, D, Majerholc, C, Guitard, F, Boué, F, Polo Devoto, J, Kansau, I, Chambrin, V, Pignon, C, Berroukeche, L, Fior, R, Martinez, V, Deback, C, Lévy, Y, Dominguez, S, Lelièvre, J.D, Lascaux, A.S, Melica, G, Billaud, E, Raffi, F, Alavena, C, Rodallec, A, Miailhes, P, Peyramond, D, Chidiac, C, Ader, F, Biron, F, Boibieux, A, Cotte, L, Ferry, T, Perpoint, T, Koffi, J, Zoulim, F, Bailly, F, Lack, P, Maynard, M, Radenne, S, Amiri, M, Le‐Thi, T.T, Piroth, L, Chavanet, P, Duong Van Huyen, M, Buisson, M, Waldner‐Combernoux, A, Mahy, S, Binois, R, Simonet‐Lann, A.L, Croisier‐Bertin, D, Aumaître, H, Bani‐Sadr, F, Lambert, D, Nguen, Y, Rouger, C, Berger, J.L, Partrisiani, M, Gautner, P, Batard, M.L, Beniken, D, Lupin, C, Lions, C, Ritleng, A.‐S, Honoré, P, Payssan, V, Breau, S, Joulie, A, Mole, M, Bolliot, C, Touam, F, André, F, Hue, H, Larmet, L, Brochier, C, Thoirain, V, Raho‐Moussa, M, Ogoudjobi, S, Azar, M, Bornarel, D, Gohier, S, Chesnel, C, Maradan, G, Kurkdji, P, Hadjoudj, S, Malet, M, Kmiec, I, Fischer, P, Palacin, A, Pietri, M.P, Le Baut, V, Guet, P, Le Puil, S, Mebarki, M, Fior, A, Adda‐Lievin, A, Conte, V, Delaune, J, Dequae Merchadou, L, Douiri, N, Gillet, S, Gilbert, C, Jacquet, A, Kherraz, R, Lagorse, P, Mora, M, Protopopescu, C, and Rosellini, S
- Published
- 2018
- Full Text
- View/download PDF
4. Direct, indirect and total effect of HIV coinfection on the risk of non-liver-related cancer in hepatitis C virus-infected patients treated by direct-acting antivirals: a mediation analysis: a mediation analysis
- Author
-
Chalouni, M. (Mathieu), Pol, S. (Stanislas), Sogni, P. (Philippe), Fontaine, H. (Helene), Lacombe, K. (Karine), Lacombe, J. (Jean-Marc) M. (M), Esterle, L. (Laure), Dorival, C. (Céline), Bourlière, M. (Marc), Bani-Sadr, F. (Firouzé), de Ledinghen, V. (Victor), Zucman, D. (David), Larrey, D. (Dominique), Salmon, D. (Dominique), Carrat, F. (Fabrice), Wittkop, L. (Linda), Rey, D. (D), Partisani, M., Batard, M.L., Cheneau, C., Priester, M. (M), Bernard-Henry, C., De Mautort, E., Gantner, P. (Pierre), Fafi-Kremer, S. (Samira), Habersetzer, F. (Francois), Baumert, Thomas F., Doffoel, M. (Michel), Mutter, C. (Catherine), Simo-Noumbissie, P. (Pauline), and Razi, E. (Esma)
- Subjects
Aucun - Abstract
OBJECTIVES: HIV-coinfected patients experience higher incidences of non-liver-related cancers than HCV-monoinfected patients. Chronic inflammation, immunosuppression, but also higher tobacco or alcohol consumption and metabolic dysregulation could explain this higher risk. We aimed to estimate the direct, indirect and total effects of HIV coinfection on the risk of non-liver-related cancers in HCV participants treated with direct-acting antivirals (DAAs). METHODS: Up to four HCV-monoinfected participants from the ANRS CO22 HEPATHER cohort were matched by age and sex to HIV/HCV-coinfected participants from the ANRS CO13 HEPAVIH cohort. Participants were followed from DAA initiation until the occurrence of a non-liver-related cancer. Counterfactual mediation analysis was carried out to estimate the direct (chronic inflammation and immunosuppression), indirect (tobacco and alcohol consumption and metabolic syndrome) and total effect of HIV coinfection on the risk of non-liver-related cancers. RESULTS: 548 HIV/HCV-coinfected and 2016 monoinfected participants were included. Overall, HIV coinfection was associated with a 3.7-fold [95% confidence interval (CI): 1.7-7.0] higher risk of non-liver-related cancers in HCV participants. This increased risk was explained by significant direct effect [hazard ratio (HR) = 3.4, 95% CI: 1.7-6.6] but not indirect effect (HR = 1.1, 95% CI: 0.8-1.5) of HIV coinfection. CONCLUSIONS: In HCV participants treated with DAAs, the direct effect of HIV coinfection, reflecting chronic inflammation and immunosuppression, was associated with a 3.7-fold higher risk of non-liver-related cancer. By contrast, the indirect effect of HIV coinfection, reflecting higher tobacco and alcohol consumption and metabolic dysregulation, was not significantly associated with the risk of non-liver-related cancers.
- Published
- 2021
5. A Satellite Infrastructure for Health Early Warning in Post-disaster Health Management
- Author
-
Chronaki, C E, Berthier, A, Lleo, M M, Esterle, L, Lenglet, A, Simon, F, Josseran, L, Lafaye, M, Matsakis, Y, Tabasco, A, Braak, L, and Medinfo 2007: Proceedings of the 12th World Congress on Health (Medical) Informatics; Building Sustainable Health Systems
- Published
- 2007
6. Milk, rather than other foods, is associated with vertebral bone mass and circulating IGF-1 in female adolescents
- Author
-
Esterle, L., Sabatier, J.-P., Guillon-Metz, F., Walrant-Debray, O., Guaydier-Souquières, G., Jehan, F., and Garabédian, M.
- Published
- 2009
- Full Text
- View/download PDF
7. Increased mortality in HIV/HCV-coinfected compared to HCV-monoinfected patients in the DAA era due to non-liver-related death
- Author
-
Chalouni, Mathieu, primary, Pol, Stanislas, additional, Sogni, Philippe, additional, Fontaine, Hélène, additional, Lacombe, Karine, additional, Marc-Lacombe, Jean, additional, Esterle, Laure, additional, Dorival, Celine, additional, Bourlière, Marc, additional, Bani-Sadr, Firouzé, additional, de Ledinghen, Victor, additional, Zucman, David, additional, Larrey, Dominique, additional, Salmon, Dominique, additional, Carrat, Fabrice, additional, Wittkop, Linda, additional, Salmon, D., additional, Wittkop, L., additional, Sogni, P., additional, Esterle, L., additional, Trimoulet, P., additional, Izopet, J., additional, Serfaty, L., additional, Paradis, V., additional, Spire, B., additional, Carrieri, P., additional, Valantin, M.A., additional, Pialoux, G., additional, Chas, J., additional, Poizot-Martin, I., additional, Barange, K., additional, Naqvi, A., additional, Rosenthal, E., additional, Bicart-See, A., additional, Bouchaud, O., additional, Gervais, A., additional, Lascoux-Combe, C., additional, Goujard, C., additional, Lacombe, K., additional, Duvivier, C., additional, Neau, D., additional, Morlat, P., additional, Bani-Sadr, F., additional, Meyer, L., additional, Boufassa, F., additional, Autran, B., additional, Roque, A.M., additional, Solas, C., additional, Fontaine, H., additional, Costagliola, D., additional, Piroth, L., additional, Simon, A., additional, Zucman, D., additional, Boué, F., additional, Miailhes, P., additional, Billaud, E., additional, Aumaitre, H., additional, Rey, D., additional, Peytavin, G., additional, Petrov-Sanchez, V., additional, and Lebrasseur-Longuet, D., additional
- Published
- 2021
- Full Text
- View/download PDF
8. HCV cure: an appropriate moment to reduce cannabis use in people living with HIV? (ANRS CO13 HEPAVIH data).
- Author
-
Barré, Tangui, Mercié, Patrick, Lions, Caroline, Miailhes, Patrick, Zucman, David, Aumaître, Hugues, Esterle, Laure, Sogni, Philippe, Carrieri, Patrizia, Salmon-Céron, Dominique, Marcellin, Fabienne, the ANRS CO13 HEPAVIH Study Group, Salmon, D., Wittkop, L., Sogni, P., Esterle, L., Trimoulet, P., Izopet, J., Serfaty, L., and Paradis, V.
- Subjects
HIV-positive persons ,HIV infections ,CANNABIS (Genus) ,CROSS-sectional method ,HEPATITIS C ,SURVEYS ,TEMPERANCE ,MIXED infections ,LOGISTIC regression analysis ,FATIGUE (Physiology) ,SMOKING ,BEHAVIOR modification - Abstract
Background: Thanks to direct-acting antivirals, hepatitis C virus (HCV) infection can be cured, with similar rates in HCV-infected and HIV–HCV co-infected patients. HCV cure is likely to foster behavioral changes in psychoactive substance use, which is highly prevalent in people living with HIV (PLWH). Cannabis is one substance that is very commonly used by PLWH, sometimes for therapeutic purposes. We aimed to identify correlates of cannabis use reduction following HCV cure in HIV–HCV co-infected cannabis users and to characterize persons who reduced their use. Methods: We used data collected on HCV-cured cannabis users in a cross-sectional survey nested in the ANRS CO13 HEPAVIH cohort of HIV–HCV co-infected patients, to perform logistic regression, with post-HCV cure cannabis reduction as the outcome, and socio-behavioral characteristics as potential correlates. We also characterized the study sample by comparing post-cure substance use behaviors between those who reduced their cannabis use and those who did not. Results: Among 140 HIV-infected cannabis users, 50 and 5 had reduced and increased their use, respectively, while 85 had not changed their use since HCV cure. Cannabis use reduction was significantly associated with tobacco use reduction, a decrease in fatigue level, paying more attention to one's dietary habits since HCV cure, and pre-HCV cure alcohol abstinence (p = 0.063 for alcohol use reduction). Conclusions: Among PLWH using cannabis, post-HCV cure cannabis reduction was associated with tobacco use reduction, improved well-being, and adoption of healthy behaviors. The management of addictive behaviors should therefore be encouraged during HCV treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
9. Self-aware Cyber-Physical Systems
- Author
-
Bellman, K., primary, Landauer, C., additional, Dutt, N., additional, Esterle, L., additional, Herkersdorf, A., additional, Jantsch, A., additional, TaheriNejad, N., additional, Lewis, P. R., additional, Platzner, M., additional, and Tammemäe, K., additional
- Published
- 2020
- Full Text
- View/download PDF
10. Patient-reported symptoms during direct-acting antiviral treatment: A real-life study in HIV-HCV coinfected patients (ANRS CO13 HEPAVIH)
- Author
-
Marcellin, Fabienne, primary, Di Beo, Vincent, additional, Aumaitre, Hugues, additional, Mora, Marion, additional, Wittkop, Linda, additional, Duvivier, Claudine, additional, Protopopescu, Camelia, additional, Lacombe, Karine, additional, Esterle, Laure, additional, Berenger, Cyril, additional, Gilbert, Camille, additional, Bouchaud, Olivier, additional, Poizot-Martin, Isabelle, additional, Sogni, Philippe, additional, Salmon-Ceron, Dominique, additional, Carrieri, Patrizia, additional, Salmon, D., additional, Wittkop, L., additional, Sogni, P., additional, Esterle, L., additional, Trimoulet, P., additional, Izopet, J., additional, Serfaty, L., additional, Paradis, V., additional, Spire, B., additional, Carrieri, P., additional, Valantin, M.A., additional, Pialoux, G., additional, Chas, J., additional, Poizot-Martin, I., additional, Barange, K., additional, Naqvi, A., additional, Rosenthal, E., additional, Bicart-See, A., additional, Bouchaud, O., additional, Gervais, A., additional, Lascoux-Combe, C., additional, Goujard, C., additional, Lacombe, K., additional, Duvivier, C., additional, Neau, D., additional, Morlat, P., additional, Bani-Sadr, F., additional, Meyer, L., additional, Boufassa, F., additional, Autran, B., additional, Roque, A.M., additional, Solas, C., additional, Fontaine, H., additional, Costagliola, D., additional, Piroth, L., additional, Simon, A., additional, Zucman, D., additional, Boué, F., additional, Miailhes, P., additional, Billaud, E., additional, Aumaître, H., additional, Rey, D., additional, Peytavin, G., additional, Petrov-Sanchez, V., additional, Lebrasseur-Longuet, D., additional, Usubillaga, R., additional, Terris, B., additional, Tremeaux, P., additional, Katlama, C., additional, Stitou, H., additional, Cacoub, P., additional, Nafissa, S., additional, Benhamou, Y., additional, Charlotte, F., additional, Fourati, S., additional, Zaegel, O., additional, Laroche, H., additional, Tamalet, C., additional, Callard, P., additional, Bendjaballah, F., additional, Amiel, C., additional, Le Pendeven, C., additional, Marchou, B., additional, Alric, L., additional, Metivier, S., additional, Selves, J., additional, Larroquette, F., additional, Rio, V., additional, Haudebourg, J., additional, Saint-Paul, M.C., additional, De Monte, A., additional, Giordanengo, V., additional, Partouche, C., additional, Martin, A., additional, Ziol, M., additional, Baazia, Y., additional, Iwaka-Bande, V., additional, Gerber, A., additional, Uzan, M., additional, Garipuy, D., additional, Ferro-Collados, M.J., additional, Nicot, F., additional, Yazdanpanah, Y., additional, Adle-Biassette, H., additional, Alexandre, G., additional, Molina, J.M., additional, Bertheau, P., additional, Chaix, M.L., additional, Delaugerre, C., additional, Maylin, S., additional, Bottero, J., additional, Krause, J., additional, Girard, P.M., additional, Wendum, D., additional, Cervera, P., additional, Adam, J., additional, Viala, C., additional, Vittecocq, D., additional, Quertainmont, Y., additional, Teicher, E., additional, Pallier, C., additional, Lortholary, O., additional, Rouzaud, C., additional, Lourenco, J., additional, Touam, F., additional, Louisin, C., additional, Avettand-Fenoel, V., additional, Gardiennet, E., additional, Mélard, A., additional, Ochoa, A., additional, Blanchard, E., additional, Castet-Lafarie, S., additional, Cazanave, C., additional, Malvy, D., additional, Dupon, M., additional, Dutronc, H., additional, Dauchy, F., additional, Lacaze-Buzy, L., additional, Desclaux, A., additional, Bioulac-Sage, P., additional, Reigadas, S., additional, Lacoste, D., additional, Bonnet, F., additional, Bernard, N., additional, Hessamfar, J, M., additional, Paccalin, F., additional, Martell, C., additional, Pertusa, M.C., additional, Vandenhende, M., additional, Mercié, P., additional, Pistone, T., additional, Receveur, M.C., additional, Méchain, M., additional, Duau, P., additional, Rivoisy, C., additional, Faure, I., additional, Caldato, S., additional, Bellecave, P., additional, Tumiotto, C., additional, Pellegrin, J.L., additional, Viallard, J.F., additional, Lazzaro, E., additional, Greib, C., additional, Majerholc, C., additional, Brollo, M., additional, Farfour, E., additional, Polo Devoto, J., additional, Kansau, I., additional, Chambrin, V., additional, Pignon, C., additional, Berroukeche, L., additional, Fior, R., additional, Martinez, V., additional, Abgrall, S., additional, Favier, M., additional, Deback, C., additional, Lévy, Y., additional, Dominguez, S., additional, Lelièvre, J.D., additional, Lascaux, A.S., additional, Melica, G., additional, Raffi, F., additional, Allavena, C., additional, Reliquet, V., additional, Boutoille, D., additional, Biron, C., additional, Lefebvre, M., additional, Hall, N., additional, Bouchez, S., additional, Rodallec, A., additional, Le Guen, L., additional, Hemon, C., additional, Peyramond, D., additional, Chidiac, C., additional, Ader, F., additional, Biron, F., additional, Boibieux, A., additional, Cotte, L., additional, Ferry, T., additional, Perpoint, T., additional, Koffi, J., additional, Zoulim, F., additional, Bailly, F., additional, Lack, P., additional, Maynard, M., additional, Radenne, S., additional, Amiri, M., additional, Valour, F., additional, Augustin-Normand, C., additional, Scholtes, C., additional, Le-Thi, T.T., additional, Chavanet, P., additional, Duong Van Huyen, M., additional, Buisson, M., additional, Waldner-Combernoux, A., additional, Mahy, S., additional, Binois, R., additional, Simonet-Lann, A.L., additional, Croisier-Bertin, D., additional, Salmon Rousseau, A., additional, Martins, C., additional, Galim, S., additional, Lambert, D., additional, Nguyen, Y., additional, Berger, J.L., additional, Hentzien, M., additional, Brodard, V., additional, Partisani, M., additional, Batard, M.L., additional, Cheneau, C., additional, Priester, M., additional, Bernard-Henry, C., additional, de Mautort, E., additional, Gantner et S Fafi-Kremer, P., additional, Roustant, F., additional, Platterier, P., additional, Kmiec, I., additional, Traore, L., additional, Lepuil, S., additional, Parlier, S., additional, Sicart-Payssan, V., additional, Bedel, E., additional, Anriamiandrisoa, S., additional, Pomes, C., additional, Mole, M., additional, Bolliot, C., additional, Catalan, P., additional, Mebarki, M., additional, Adda-Lievin, A., additional, Thilbaut, P., additional, Ousidhoum, Y., additional, Makhoukhi, F.Z., additional, Braik, O., additional, Bayoud, R., additional, Gatey, C., additional, Pietri, M.P., additional, Le Baut, V., additional, Ben Rayana, R., additional, Bornarel, D., additional, Chesnel, C., additional, Beniken, D., additional, Pauchard, M., additional, Akel, S., additional, Lions, C., additional, Ivanova, A., additional, Ritleg, A.-S., additional, Debreux, C., additional, Chalal, L., additional, Zelie, J., additional, Hue, H., additional, Soria, A., additional, Cavellec, M., additional, Breau, S., additional, Joulie, A., additional, Fisher, P., additional, Gohier, S., additional, Ogoudjobi, S., additional, Brochier, C., additional, Thoirain-Galvan, V., additional, Le Cam, M., additional, Chalouni, M., additional, Conte, V., additional, Dequae-Merchadou, L., additional, Desvallees, M., additional, Gilbert, C., additional, Gillet, S., additional, Knight, R., additional, Lemboub, T., additional, Marcellin, F., additional, Michel, L., additional, Mora, M., additional, Protopopescu, C., additional, Roux, P., additional, Tezkratt, S., additional, Barré, T., additional, Baudoin, M., additional, Santos, M., additional, Di Beo, V., additional, and Nishimwe, M., additional
- Published
- 2020
- Full Text
- View/download PDF
11. P5341Predictive factors of atherosclerotic cardiovascular diseases events in HIV-HVC co-infected patients: results from hepavih ANRS co13 cohort
- Author
-
Boccara, F, primary, Tan, B K, additional, Chalouni, M, additional, Salmon Ceron, D, additional, Cinaud, A, additional, Esterle, L, additional, Gilbert, C, additional, Bani-Sadr, F, additional, Dabis, F, additional, Sogni, P, additional, and Wittkop, L, additional
- Published
- 2019
- Full Text
- View/download PDF
12. Trusting Intelligent Machines
- Author
-
Andras, PE, Esterle, L, Guckert, M, Han, TA, Lewis, PR, Milanovic, K, Payne, T, Perret, C, Pitt, J, Powers, ST, Urquhart, N, and Wells, S
- Subjects
QA75 ,Q335 - Abstract
Intelligent machines have reached capabilities that go beyond a level that a human being can fully comprehend without sufficiently detailed understanding of the underlying mechanisms. The choice of moves in the game Go (generated by Deep Mind?s Alpha Go Zero [1]) are an impressive example of an artificial intelligence system calculating results that even a human expert for the game can hardly retrace [2]. But this is, quite literally, a toy example. In reality, intelligent algorithms are encroaching more and more into our everyday lives, be it through algorithms that recommend products for us to buy, or whole systems such as driverless vehicles. We are delegating ever more aspects of our daily routines to machines, and this trend looks set to continue in the future. Indeed, continued economic growth is set to depend on it. The nature of human-computer interaction in the world that the digital transformation is creating will require (mutual) trust between humans and intelligent, or seemingly intelligent, machines. But what does it mean to trust an intelligent machine? How can trust be established between human societies and intelligent machines?
- Published
- 2018
13. Daily cannabis and reduced risk of steatosis in human immunodeficiency virus and hepatitis C virus-co-infected patients (ANRS CO13-HEPAVIH)
- Author
-
Dabis, F., Chas, J., Rey, D., Wittkop, L., Sogni, P., Carrieri, P., Grp, ANRS CO13 HEPAVIH Study, Nordmann, S., Vilotitch, A., Roux, P., Esterle, L., Spire, B., Marcellin, F., Salmon-Ceron, D., DUFOUR, Jean-Charles, Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD), and Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)
- Subjects
Male ,[SDV]Life Sciences [q-bio] ,HIV Infections ,Hepacivirus ,medicine.disease_cause ,0302 clinical medicine ,Risk Factors ,Surveys and Questionnaires ,Prospective Studies ,030212 general & internal medicine ,Ultrasonography ,education.field_of_study ,biology ,Coinfection ,Lamivudine ,Middle Aged ,Hepatitis C ,3. Good health ,[SDV] Life Sciences [q-bio] ,Infectious Diseases ,Liver ,Cohort ,Female ,030211 gastroenterology & hepatology ,France ,medicine.drug ,Adult ,medicine.medical_specialty ,Hepatitis C virus ,Population ,Marijuana Smoking ,03 medical and health sciences ,Virology ,Internal medicine ,medicine ,Humans ,education ,Hepatology ,business.industry ,Odds ratio ,medicine.disease ,biology.organism_classification ,Fatty Liver ,Cross-Sectional Studies ,Logistic Models ,Cannabis ,Insulin Resistance ,Steatosis ,business ,Body mass index - Abstract
Summary Liver steatosis is common in human immunodeficiency virus (HIV)-hepatitis C virus (HCV)-co-infected patients. Some recent studies have found that cannabis use is negatively associated with insulin resistance in the general population and in HIV-HCV-co-infected patients. Given the causal link between insulin resistance and steatosis, we hypothesized that cannabis use has a positive impact on steatosis. Therefore, we aimed to study whether cannabis use in this population was associated with a reduced risk of steatosis, measured by ultrasound examination. ANRS CO13-HEPAVIH is a French nationwide multicentre cohort of HIV-HCV-co-infected patients. Medical and socio-behavioural data from clinical follow-up visits and annual self-administered questionnaires were prospectively collected. A cross-sectional analysis was conducted using data from the first visit where both ultrasound examination data for steatosis (positive or negative diagnosis) and data on cannabis use were available. A logistic regression model was used to evaluate the association between cannabis use and steatosis. Among study sample patients (n = 838), 40.1% had steatosis. Fourteen per cent reported daily cannabis use, 11.7% regular use and 74.7% no use or occasional use (“never or sometimes”). Daily cannabis use was independently associated with a reduced prevalence of steatosis (adjusted odds ratio [95% CI] = 0.64 [0.42;0.99]; P = .046), after adjusting for body mass index, hazardous alcohol consumption and current or lifetime use of lamivudine/zidovudine. Daily cannabis use may be a protective factor against steatosis in HIV-HCV-co-infected patients. These findings confirm the need for a clinical evaluation of cannabis-based pharmacotherapies in this population. Eudract.ema.europa.eu number, DGS050367.
- Published
- 2018
14. eHealth Consumer Attitudes in Greece and Denmark
- Author
-
Orphanoudaki, E, Voss, H, Kouroubali, A, Roumeliotaki, T, Esterle, L, Chronaki, C E, and Medinfo 2007: Proceedings of the 12th World Congress on Health (Medical) Informatics; Building Sustainable Health Systems
- Published
- 2007
15. HCV-Related Mortality Among HIV/HCV Co-infected Patients: The Importance of Behaviors in the HCV Cure Era (ANRS CO13 HEPAVIH Cohort).
- Author
-
Santos, Melina Erica, Protopopescu, Camelia, Sogni, Philippe, Yaya, Issifou, Piroth, Lionel, Bailly, François, Marcellin, Fabienne, Esterle, Laure, Wittkop, Linda, Rosenthal, Eric, Morlat, Philippe, Roux, Perrine, de Araujo, Wildo Navegantes, Salmon-Ceron, Dominique, Carrieri, Maria Patrizia, the ANRS CO13 HEPAVIH Study Group, Salmon, D., Wittkop, L., Sogni, P., and Esterle, L.
- Subjects
REGULATION of body weight ,CONFIDENCE intervals ,HEALTH behavior ,HEPATITIS C ,HIV-positive persons ,RISK assessment ,SUBSTANCE abuse ,DESCRIPTIVE statistics ,MIXED infections - Abstract
Mortality among individuals co-infected with HIV and hepatitis C virus (HCV) is relatively high. We evaluated the association between psychoactive substance use and both HCV and non-HCV mortality in HIV/HCV co-infected patients in France, using Fine and Gray's competing-risk model adjusted for socio-demographic, clinical predictors and confounding factors, while accounting for competing causes of death. Over a 5-year median follow-up period, 77 deaths occurred among 1028 patients. Regular/daily cannabis use, elevated coffee intake, and not currently smoking were independently associated with reduced HCV-mortality (adjusted sub-hazard ratio [95% CI] 0.28 [0.10–0.83], 0.38 [0.15–0.95], and 0.28 [0.10–0.79], respectively). Obesity and severe thinness were associated with increased HCV-mortality (2.44 [1.00–5.93] and 7.25 [2.22–23.6] versus normal weight, respectively). Regular binge drinking was associated with increased non-HCV-mortality (2.19 [1.10–4.37]). Further research is needed to understand the causal mechanisms involved. People living with HIV/HCV co-infection should be referred for tobacco, alcohol and weight control interventions and potential benefits of cannabis-based therapies investigated. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
16. Impact of elevated coffee intake on the risk of advanced liver fibrosis in HIV-HCV co-infected patients of the French ANRS CO13 HEPAVIH cohort: a sex-based analysis
- Author
-
Yaya, I., primary, Protopopescu, C., additional, Marcellin, F., additional, Esterle, L., additional, Wittkop, L., additional, Duvivier, C., additional, Piroth, L., additional, Sogni, P., additional, Salmon-Ceron, D., additional, and Carrieri, M.P., additional
- Published
- 2018
- Full Text
- View/download PDF
17. Protective effect of cannabis and coffee consumption on HCV-related mortality in French HIV-HCV co-infected patients (ANRS CO13 HEPAVIH cohort)
- Author
-
Protopopescu, C., primary, Santos, M.E., additional, Sogni, P., additional, Marcellin, F., additional, Esterle, L., additional, Wittkop, L., additional, Rosenthal, E., additional, Morlat, P., additional, Roux, P., additional, de Araújo, W.N., additional, Salmon-Céron, D., additional, and Carrieri, M.P., additional
- Published
- 2018
- Full Text
- View/download PDF
18. Persistance du risque de décès et d’évènement hépatique après guérison de l’hépatite C chez les patients coinfectés VIH/VHC–cohorte ANRS CO13 Hepavih
- Author
-
Salmon, D., primary, Gilbert, C., additional, Bottero, J., additional, Sogni, P., additional, Esterle, L., additional, Piroth, L., additional, and Bani-Sadr, F., additional
- Published
- 2017
- Full Text
- View/download PDF
19. La durée d’infection VIH est indépendamment associée au cancer non liés au VIH et au VHC chez les patients co-infectés VIH/VHC
- Author
-
Billa, O., primary, Bani-Sadr, F., additional, Poizot-Martin, I., additional, Sogni, P., additional, Rey, D., additional, Chas, J., additional, Bottero, J., additional, Esterle, L., additional, Salmon, D., additional, and Wittkop, L., additional
- Published
- 2017
- Full Text
- View/download PDF
20. HIV/HCV-coinfected cirrhotic patients are no longer at higher risk of hepatocellular carcinoma or end-stage liver disease as compared to HCV-monoinfected patients (ANRS CO12 CirVir and ANRS CO13 HEPAVIH cohorts)
- Author
-
Salmon, D., primary, Nahon, P., additional, Layese, R., additional, Bourcier, V., additional, Audureau, E., additional, Gilbert, C., additional, Esterle, L., additional, Dabis, F., additional, Wittkop, L., additional, and Roudot-Thoraval, F., additional
- Published
- 2017
- Full Text
- View/download PDF
21. Risques environnementaux de l’hypospade commun : une approche géographique
- Author
-
Bougnères, P., primary, Esterle, L., additional, Mouriquand, P., additional, and Valleron, A.-J., additional
- Published
- 2016
- Full Text
- View/download PDF
22. THU-109 - Impact of elevated coffee intake on the risk of advanced liver fibrosis in HIV-HCV co-infected patients of the French ANRS CO13 HEPAVIH cohort: a sex-based analysis
- Author
-
Yaya, I., Protopopescu, C., Marcellin, F., Esterle, L., Wittkop, L., Duvivier, C., Piroth, L., Sogni, P., Salmon-Ceron, D., and Carrieri, M.P.
- Published
- 2018
- Full Text
- View/download PDF
23. THU-048 - Protective effect of cannabis and coffee consumption on HCV-related mortality in French HIV-HCV co-infected patients (ANRS CO13 HEPAVIH cohort)
- Author
-
Protopopescu, C., Santos, M.E., Sogni, P., Marcellin, F., Esterle, L., Wittkop, L., Rosenthal, E., Morlat, P., Roux, P., de Araújo, W.N., Salmon-Céron, D., and Carrieri, M.P.
- Published
- 2018
- Full Text
- View/download PDF
24. Appui au système national de la recherche (SNR) au Maroc pour une intégration à l'Espace européen de recherche (EER) : jumelage institutionnel MA09/ENP-AP/OT14 : rapport final pour l'activité A.3.4. Elaborer des propositions en vue de la création d'un 'observatoire' de la science et de la technologie au Maroc (OSTM)
- Author
-
Esterle, L. and Gaillard, Jacques
- Subjects
RECHERCHE DEVELOPPEMENT ,EXPERTISE ,COOPERATION SCIENTIFIQUE ,INNOVATION ,EVALUATION ,OBSERVATOIRE ,RECHERCHE SCIENTIFIQUE ,DONNEES STATISTIQUES - Published
- 2012
25. CO-62 – Syndrome de Rett et déterminants de la fragilité osseuse
- Author
-
Rothenbuhler, A., primary, Esterle, L., additional, Lahlou, N., additional, Bienvenu, T., additional, Bahi-Buisson, N., additional, and Linglart, A., additional
- Published
- 2015
- Full Text
- View/download PDF
26. LP20 : Safety and efficacy of all-oral daa regimens in HIV-HCV coinfected cirrhotic patients from the prospective ANRS CO13 - HEPAVIH cohort
- Author
-
Sogni, P., primary, Gilbert, C., additional, Lacombe, K., additional, Piroth, L., additional, Rosenthal, E., additional, Dominguez, S., additional, Chas, J., additional, Neau, D., additional, Poizot-Martin, I., additional, Gervais Hasenknopf, A., additional, Morlat, P., additional, Simon, A., additional, Zucman, D., additional, Aumaitre, H., additional, Lascoux-Combe, C., additional, Esterle, L., additional, Dabis, F., additional, Wittkop, L., additional, and Salmon-Ceron, D., additional
- Published
- 2015
- Full Text
- View/download PDF
27. Gearing European research towards sustainability - 'RD4SD'Exercise
- Author
-
Georghiou, L., Cassingena-Harper, J., Esterle, L., and Kuhlmann, Stefan
- Subjects
METIS-264333 - Published
- 2009
28. Mise au point sur la prise en charge chirurgicale des anomalies congénitales du développement génito-sexuel (Disorders of Sex Development: DSD)
- Author
-
Mouriquand, P., primary, Mouriquand, P., additional, Bouvattier, C., additional, Chatelain, P., additional, Bougnère, P., additional, Brindusa Gorduza, D., additional, Gay, C.-L., additional, Duranteau, L., additional, Morel, Y., additional, Tardy, V., additional, Plotton, I., additional, Lejeune, H., additional, Brac de la Perrière, A., additional, Tamet, J.-Y., additional, and Esterle, L., additional
- Published
- 2014
- Full Text
- View/download PDF
29. État des lieux après inclusion de 162 patients dans le PHRC national Y-BLOC21 « évaluation de la sexualité et de la fertilité des hommes nés avec une forme classique de déficit en 21 hydroxylase »
- Author
-
Esterle, L., primary, Tardy, V., additional, Renoult-Pierre, P., additional, Christin-Maitre, S., additional, Kerlan, V., additional, Bertherat, J., additional, Kuhn, J.M., additional, Caron, P., additional, Chabre, O., additional, Dewailly, D., additional, Touraine, P., additional, Young, J., additional, and Bouvattier, C., additional
- Published
- 2012
- Full Text
- View/download PDF
30. High prevalence of genu varum/valgum in European children with low vitamin D status and insufficient dairy products/calcium intakes
- Author
-
Voloc, A, primary, Esterle, L, additional, Nguyen, T M, additional, Walrant-Debray, O, additional, Colofitchi, A, additional, Jehan, F, additional, and Garabedian, M, additional
- Published
- 2010
- Full Text
- View/download PDF
31. Between Clinical Medicine and the Laboratory: Medical Research Funding in France from 1945 to the Present
- Author
-
Esterle, L., primary and Picard, J.-F., additional
- Published
- 2010
- Full Text
- View/download PDF
32. Calcium et santé osseuse chez l’enfant et l’adolescent
- Author
-
Esterle, L., primary
- Published
- 2010
- Full Text
- View/download PDF
33. Besoins en calcium de l’adolescent
- Author
-
Garabédian, M., primary and Esterle, L., additional
- Published
- 2009
- Full Text
- View/download PDF
34. Milk, rather than other foods, is associated with vertebral bone mass and circulating IGF-1 in female adolescents
- Author
-
Esterle, L., primary, Sabatier, J.-P., additional, Guillon-Metz, F., additional, Walrant-Debray, O., additional, Guaydier-Souquières, G., additional, Jehan, F., additional, and Garabédian, M., additional
- Published
- 2008
- Full Text
- View/download PDF
35. Indexing Digital Images Based on Overlap.
- Author
-
Esterle, L. and Lux, M.
- Published
- 2011
- Full Text
- View/download PDF
36. A socio-economic approach to online vision graph generation and handover in distributed smart camera networks.
- Author
-
Esterle, L., Lewis, P.R., Bogdanski, M., Rinner, B., and Xin Yao
- Published
- 2011
- Full Text
- View/download PDF
37. A high-fat diet induces lower expression of retinoid receptors and their target genes GAP-43/neuromodulin and RC3/neurogranin in the rat brain.
- Author
-
Buaud B, Esterle L, Vaysse C, Alfos S, Combe N, Higueret P, and Pallet V
- Published
- 2010
- Full Text
- View/download PDF
38. A Satellite Infrastructure for Health Early Warning in Post-Disaster Health Management.
- Author
-
Kuhn, Klaus A., Warren, James R., Leong, Tze-Yun, Chronaki, C.E., Berthier, A., Lleo, M.M., Esterle, L., Lenglet, A., Simon, F., Josseran, L., Lafaye, M., Matsakis, Y., Tabasco, A., and Braak, L.
- Abstract
The risk of epidemics and emerging or re-emerging diseases such as avian flu, tuberculosis, malaria and other vector-borne diseases, is rising. These risks can be contained with prevention, early warning, and prompt management. Despite progress in information technology, communication is still a bottleneck for health early warning and response systems in post-disaster situations. This paper presents Satellites for Epidemiology (SAFE), a component-based interoperable architecture for health early warning that employs satellite, radio, and wireless networks, geographic information systems, integration technology, and data mining to promptly identify and respond to a disease outbreak. In a post-disaster situation, a mobile health emergency coordination center is established and integrated to public health services for health monitoring. The added-value of SAFE for post-disaster health management will be demonstrated as part of an earthquake readiness exercise regarding a typhoid fever epidemic, in the island of Crete. Advanced communication and data mining techniques in SAFE offer new tools to the “Epidemic Intelligence” and contribute to advanced preparedness and prompt response by lifting communication barriers, promoting collaboration, and reducing the isolation of affected areas. [ABSTRACT FROM AUTHOR]
- Published
- 2007
39. A satellite infrastructure for health early warning in post-disaster health management
- Author
-
Catherine Chronaki, Berthier, A., Lleo, M. M., Esterle, L., Lenglet, A., Simon, F., Josseran, L., Lafaye, M., Matsakis, Y., Tabasco, A., and Braak, L.
- Subjects
Disasters ,Emergency Medical Service Communication Systems ,Population Surveillance ,Geographic Information Systems ,Humans ,Satellite Communications ,Telemedicine ,Disease Outbreaks - Abstract
The risk of epidemics and emerging or re-emerging diseases such as avian flu, tuberculosis, malaria and other vector-borne diseases, is rising. These risks can be contained with prevention, early warning, and prompt management. Despite progress in information technology, communication is still a bottleneck for health early warning and response systems in post-disaster situations. This paper presents Satellites for Epidemiology (SAFE), a component-based interoperable architecture for health early warning that employs satellite, radio, and wireless networks, geographic information systems, integration technology, and data mining to promptly identify and respond to a disease outbreak. In a post-disaster situation, a mobile health emergency coordination center is established and integrated to public health services for health monitoring. The added-value of SAFE for post-disaster health management will be demonstrated as part of an earthquake readiness exercise regarding a typhoid fever epidemic, in the island of Crete. Advanced communication and data mining techniques in SAFE offer new tools to the "Epidemic Intelligence" and contribute to advanced preparedness and prompt response by lifting communication barriers, promoting collaboration, and reducing the isolation of affected areas.
40. Editorial: Understanding and engineering cyber-physical collectives.
- Author
-
Casadei R, Esterle L, Gamble R, Harvey P, and Wanner EF
- Abstract
Competing Interests: Author PH was employed by company Rakuten Mobile Innovation Studio. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
- Published
- 2024
- Full Text
- View/download PDF
41. Early humoral response to COVID-19 vaccination in patients living with obesity and diabetes in France. The COVPOP OBEDIAB study with results from the ANRS0001S COV-POPART cohort.
- Author
-
Gaborit B, Fernandes S, Loubet P, Ninove L, Dutour A, Cariou B, Coupaye M, Clement K, Czernichow S, Carette C, Resseguier N, Esterle L, Kali S, Houssays M, de Lamballerie X, Wittkop L, Launay O, and Laville M
- Subjects
- Humans, COVID-19 Vaccines, Prospective Studies, SARS-CoV-2, Vaccination, Obesity complications, France epidemiology, Diabetes Mellitus, Type 2, COVID-19 prevention & control
- Abstract
Background: Patients with diabetes and obesity are populations at high-risk for severe COVID-19 outcomes and have shown blunted immune responses when administered different vaccines. Here we used the 'ANRS0001S COV-POPART' French nationwide multicenter prospective cohort to investigate early humoral response to COVID-19 vaccination in the sub-cohort ('COVPOP OBEDIAB') of patients with obesity and diabetes., Methods: Patients with diabetes (n = 390, type 1 or 2) or obesity (n = 357) who had received two vaccine doses and had no history of previous COVID-19 infection and negative anti-nucleocapsid (NCP) antibodies were included and compared against healthy subjects (n = 573). Humoral response was assessed at baseline, at one month post-first dose (M0) and one-month post-second dose (M1), through percentage of responders (positive anti-spike SARS-CoV-2 IgG antibodies (Sabs), geometric means of Sabs; BAU/mL), proportion of individuals with anti-RBD antibodies, and proportion of individuals with anti-SARS-CoV-2-specific neutralizing antibodies (Nabs). Potential clinical and biological factors associated with weak response (defined as Sabs < 264 BAU/mL) and presence of non-reactive anti-RBD antibodies at M1 were evaluated. Univariate and multivariate regressions were performed to estimate crude and adjusted coefficients with 95 % confidence intervals. Poor glycemic control was defined as HbA1c ≥ 7.5 % at inclusion., Results: Patients with diabetes, particularly type 2 diabetes, and patients with obesity were less likely to have positive Sabs and anti-RBD antibodies after the first and second dose compared to controls (p < 0.001). At M1, we found Sabs seroconversion in 94.1 % of patients with diabetes versus 99.7 % in controls, anti-RBD seroconversion in 93.8 % of patients with diabetes versus 99.1 % in controls, and Nabs seroconversion in 95.7 % of patients with diabetes versus 99.6 % in controls (all p < 0.0001). Sabs and anti-RBD seroconversion at M0 and M1 were also significantly lower in obese patients than controls, at respectively 82.1 % versus 89.9 % (p = 0.001; M0 Sabs), 94.4 % versus 99.7 % (p 0.001; M1 Sabs), 79.0 % vs 86.2 % (p = 0.004 M0 anti-RBD), and 96.99 % vs 99.1 % (p = 0.012 M1 anti-RBD). The factors associated with low vaccine response (BAU < 264/mL) in patients with diabetes were chronic kidney disease (adjusted OR = 6.88 [1.77;26.77], p = 0.005) and poor glycemic control (adjusted OR = 3.92 [1.26;12.14], p = 0.018). In addition, BMI ≥ 40 kg/m
2 was found to be associated with a higher vaccine response (adjusted OR = 0.10 [0.01;0.91], p = 0.040) than patients with BMI < 40 kg/m2 ., Conclusion: COVID-19 vaccine humoral response was lower in patients with obesity and diabetes one month after second dose compared to controls, especially in diabetic patients with CKD or inadequate glycemic control. These findings point to the need for post-vaccination serological checks in these high-risk populations., Competing Interests: Declaration of competing interest None., (Copyright © 2023 Elsevier Inc. All rights reserved.)- Published
- 2023
- Full Text
- View/download PDF
42. One-month humoral response following two or three doses of messenger RNA coronavirus disease 2019 vaccines as primary vaccination in specific populations in France: first results from the Agence Nationale Recherche contre le Sida (ANRS)0001S COV-POPART cohort.
- Author
-
Loubet P, Wittkop L, Ninove L, Chalouni M, Barrou B, Blay JY, Hourmant M, Thouvenot E, Laville M, Laviolle B, Lelievre JD, Morel J, Quoc SN, Spano JP, Terrier B, Thiebaut A, Viallard JF, Vrtovsnik F, Circosta S, Esterle L, Levier A, Vanhems P, Tartour E, Parfait B, de Lamballerie X, and Launay O
- Subjects
- Adult, Humans, Prospective Studies, SARS-CoV-2, France, Antibodies, Neutralizing, Antibodies, Viral, Immunoglobulin G, Vaccination, COVID-19 Vaccines, COVID-19
- Abstract
Objectives: We aimed to investigate the 1-month humoral response to two or three doses of a messenger RNA coronavirus disease 2019 (COVID-19) vaccine as a primary vaccination regimen in specific populations compared with that in healthy adults., Methods: Agence Nationale Recherche contre le Sida (ANRS)0001S-COV-POPART (NCT04824651) is a French nation-wide, multi-centre, prospective, observational cohort study assessing the immune response to COVID-19 vaccines routinely administered to 11 sub-groups of patients with chronic conditions and two control groups. Patients and controls who received at least two vaccine doses and whose results 1 month after the second dose were available were included. The humoral response was assessed 1 month after the first, second and third doses (if applicable) based on the percentage of responders (positive for anti-Spike severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] IgG antibodies), geometric means of anti-Spike SARS-CoV-2 IgG antibodies (enzyme-linked immunosorbent assay) and proportion of participants with anti-SARS-CoV-2-specific neutralizing antibodies (in vitro neutralization assay for the original SARS-CoV-2 strain). All analyses were centralized., Results: We included 4091 participants in this analysis: 2979 participants from specific sub-populations and 1112 controls. Only 522 (17.5%) participants from the specific populations received three doses as a primary vaccination regimen. Patients living with human immunodeficiency virus, cancer and diabetes had high percentages of responders after two doses, whereas patients with solid organ transplants, allogeneic hematopoietic stem cell transplants and hypogammaglobulinaemia had the lowest percentage of responders (35.9% [95% CI, 29.2-43.0], 57.4% [95% CI, 48.1-66.3] and 77.1% [95% CI, 65.6-86.3], respectively). In those who received the third dose, the percentage of responders reached 54.2% (95% CI, 42.9-65.2) (vs. 32.3% [95% CI, 16.7-51.4] after 2 doses) among those with solid organ transplants and 73.9% (95% CI, 58.9-85.7) (vs. 56.1% [95% CI, 46.2-65.7] after 2 doses) among those with hematopoietic stem cell transplants. Similar results were found with anti-SARS-CoV-2-specific neutralizing antibodies., Conclusions: A lower humoral response to COVID-19 vaccines was observed in the specific populations compared with that in the controls. The third dose of this vaccine in the primary regimen had a positive effect on the percentages of patients who developed anti-Spike IgG antibodies and specific neutralizing antibodies., (Copyright © 2022 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
43. HCV Cure and Cannabis Abstinence Facilitate Tobacco Smoking Quit Attempts in HIV-HCV Co-Infected Patients (ANRS CO13 HEPAVIH Cohort Study).
- Author
-
Barré T, Mercié P, Marcellin F, Esterle L, Duvivier C, Teicher E, Bureau M, Chas J, Salmon-Céron D, Sogni P, Carrieri MP, Wittkop L, and Protopopescu C
- Subjects
- Cohort Studies, Hepacivirus, Humans, Tobacco Smoking, Cannabis, Coinfection, HIV Infections complications, HIV Infections drug therapy, HIV Infections epidemiology, Hepatitis C complications, Hepatitis C drug therapy, Hepatitis C epidemiology
- Abstract
In Western countries, tobacco smoking is highly prevalent among patients co-infected with HIV and hepatitis C virus (HCV). In the era of antiretrovirals and HCV cure, smoking-related health damages contribute greatly to morbidity and mortality in HIV-HCV co-infected patients. We used longitudinal data from the ANRS CO13 HEPAVIH cohort to identify the correlates of tobacco smoking quit attempts (TSQA) in HIV-HCV co-infected patients. TSQA were modelled using a multivariable discrete-time Cox proportional hazards model in 695 HIV-HCV co-infected tobacco smokers. HCV cure was associated with a 76% higher chance of TSQA (adjusted hazard ratio [95% confidence interval]: 1.76 [1.06-2.93], p = 0.029), and cannabis use with a 37% lower chance (0.63 [0.40-1.00], p = 0.049), independently of the mode of HIV transmission, other psychoactive substance use, and body mass index. Patients should be screened for tobacco and cannabis use at HCV treatment initiation and during follow-up. They should also be provided with comprehensive counselling and referral to addiction services. Non-smoking routes of cannabis administration should be promoted for cannabis users who wish to quit smoking tobacco., (© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2021
- Full Text
- View/download PDF
44. Post-HCV cure self-reported changes in physical activity, eating behaviours, and fatigue in people living with HIV (ANRS CO13 HEPAVIH).
- Author
-
Marcellin F, Di Beo V, Esterle L, Abgrall S, Pialoux G, Barré T, Wittkop L, Salmon-Ceron D, Sogni P, and Carrieri P
- Subjects
- Exercise, Fatigue epidemiology, Fatigue etiology, Feeding Behavior, Humans, Self Report, Coinfection epidemiology, HIV Infections complications, Hepatitis C complications, Hepatitis C drug therapy, Hepatitis C epidemiology
- Published
- 2021
- Full Text
- View/download PDF
45. Direct, indirect and total effect of HIV coinfection on the risk of non-liver-related cancer in hepatitis C virus-infected patients treated by direct-acting antivirals: a mediation analysis.
- Author
-
Chalouni M, Pol S, Sogni P, Fontaine H, Lacombe K, Lacombe JM, Esterle L, Dorival C, Bourlière M, Bani-Sadr F, de Ledinghen V, Zucman D, Larrey D, Salmon D, Carrat F, Wittkop L, and Martinez V
- Subjects
- Antiviral Agents pharmacology, Antiviral Agents therapeutic use, Hepacivirus, Humans, Mediation Analysis, Sustained Virologic Response, Coinfection drug therapy, HIV Infections complications, HIV Infections drug therapy, HIV Infections epidemiology, Hepatitis C complications, Hepatitis C drug therapy, Hepatitis C, Chronic complications, Hepatitis C, Chronic drug therapy, Hepatitis C, Chronic epidemiology, Neoplasms complications, Neoplasms epidemiology
- Abstract
Objectives: HIV-coinfected patients experience higher incidences of non-liver-related cancers than HCV-monoinfected patients. Chronic inflammation, immunosuppression, but also higher tobacco or alcohol consumption and metabolic dysregulation could explain this higher risk. We aimed to estimate the direct, indirect and total effects of HIV coinfection on the risk of non-liver-related cancers in HCV participants treated with direct-acting antivirals (DAAs)., Methods: Up to four HCV-monoinfected participants from the ANRS CO22 HEPATHER cohort were matched by age and sex to HIV/HCV-coinfected participants from the ANRS CO13 HEPAVIH cohort. Participants were followed from DAA initiation until the occurrence of a non-liver-related cancer. Counterfactual mediation analysis was carried out to estimate the direct (chronic inflammation and immunosuppression), indirect (tobacco and alcohol consumption and metabolic syndrome) and total effect of HIV coinfection on the risk of non-liver-related cancers., Results: 548 HIV/HCV-coinfected and 2016 monoinfected participants were included. Overall, HIV coinfection was associated with a 3.7-fold [95% confidence interval (CI): 1.7-7.0] higher risk of non-liver-related cancers in HCV participants. This increased risk was explained by significant direct effect [hazard ratio (HR) = 3.4, 95% CI: 1.7-6.6] but not indirect effect (HR = 1.1, 95% CI: 0.8-1.5) of HIV coinfection., Conclusions: In HCV participants treated with DAAs, the direct effect of HIV coinfection, reflecting chronic inflammation and immunosuppression, was associated with a 3.7-fold higher risk of non-liver-related cancer. By contrast, the indirect effect of HIV coinfection, reflecting higher tobacco and alcohol consumption and metabolic dysregulation, was not significantly associated with the risk of non-liver-related cancers., (© 2021 British HIV Association.)
- Published
- 2021
- Full Text
- View/download PDF
46. Risk of severe clinical events after sustained virological response following direct-acting antiviral therapy in HIV and hepatitis C virus coinfected participants.
- Author
-
Chalouni M, Wittkop L, Bani-Sadr F, Lacombe K, Esterle L, Gilbert C, Miailhes P, Zucman D, Valantin MA, Brégigeon-Ronot S, Morlat P, Billaud E, Piroth L, Naqvi A, Sogni P, and Salmon D
- Subjects
- Antiviral Agents therapeutic use, Hepacivirus, Humans, Liver Cirrhosis epidemiology, Prospective Studies, Treatment Outcome, Coinfection complications, Coinfection drug therapy, HIV Infections complications, HIV Infections drug therapy, HIV Infections epidemiology, Hepatitis C complications, Hepatitis C drug therapy, Hepatitis C epidemiology, Hepatitis C, Chronic complications, Hepatitis C, Chronic drug therapy
- Abstract
Objectives: Sustained virological response (SVR) decreases the risk of hepatitis C virus (HCV)-related events. Nevertheless, a substantial risk of events persists. We estimated incidences and identified factors associated with severe clinical events after SVR following treatment with a direct-acting antiviral (DAA) in HIV/HCV-coinfected patients., Methods: Participants from the ANRS CO13 HEPAVIH were included if they reached SVR. Incidence rates of overall mortality, liver-related events, AIDS-defining events, ischaemic events and non-liver non-AIDS-defining cancers (NLNA) were estimated. Factors associated with the risk of those events were identified using Poisson models adjusted on age at SVR and sex., Results: In all, 775 participants were included. Incidence rates (95% confidence interval) of liver-related events, overall mortality, AIDS-defining events, ischaemic events and NLNA cancers per 1000 person-years were 5.9 (3.3-10.3), 22.2 (16.8-29.5), 0.6 (0.1-4.5), 7.3 (4.4-12.2) and 13.7 (9.4-20.0), respectively. For all events, incidence rates were higher in cirrhotic than in non-cirrhotic participants. Cirrhosis, liver stiffness and CD4 count were associated with liver-related events. Factors associated with overall mortality were age, cirrhosis, liver stiffness and gamma-glutamyl transferase (GGT). For ischaemic events and NLNA cancers, associated factors were total cholesterol and CD4 count, respectively., Conclusions: After SVR following a DAA treatment, liver-related and AIDS-defining events were observed less frequently than NLNA cancers. Severity of liver disease was associated with the risk of liver-related events and of overall mortality but not with ischaemic events and NLNA cancers. Factors reflecting HIV infection were associated with NLNA cancers and liver-related events., (© 2021 British HIV Association.)
- Published
- 2021
- Full Text
- View/download PDF
47. Cannabis use and reduced risk of elevated fatty liver index in HIV-HCV co-infected patients: a longitudinal analysis (ANRS CO13 HEPAVIH).
- Author
-
Barré T, Rojas Rojas T, Lacombe K, Protopopescu C, Poizot-Martin I, Nishimwe ML, Zucman D, Esterle L, Billaud E, Aumaitre H, Bouchaud O, Rey D, Piroth L, Salmon-Ceron D, Wittkop L, Sogni P, Carrieri MP, Serfaty L, and Marcellin F
- Subjects
- Adult, Cohort Studies, Coinfection, Fatty Liver etiology, Fatty Liver prevention & control, Female, Follow-Up Studies, Humans, Longitudinal Studies, Male, Middle Aged, Prospective Studies, Risk Factors, Fatty Liver epidemiology, HIV Infections complications, Hepatitis C complications, Marijuana Use epidemiology
- Abstract
Background : Cannabis use and elevated fatty liver index (FLI≥ 60) (a biomarker of hepatic steatosis in the general population) have been identified as predictors of HCV-related and overall mortality, respectively, in HIV-HCV co-infected patients. However, the relationship between cannabis use and the risk of elevated FLI has never been explored. Methods : Using five-year follow-up data from 997 HIV-HCV co-infected patients (ANRS CO13 HEPAVIH cohort), we analyzed the relationship between cannabis use and FLI using mixed-effects multivariable logistic (outcome: elevated FLI yes/no) and linear (outcome: continuous FLI) regression models. Results : At the last follow-up visit, 27.4% of patients reported regular or daily cannabis use and 27.8% had elevated FLI. After multivariable adjustment, regular or daily cannabis use was associated with a 55% lower risk of elevated FLI (adjusted odds ratio [95% confidence interval]: 0.45 [0.22; 0.94]; p = 0.033) and lower FLI values (adjusted model coefficient: -4.24 [-6.57; -1.91], p < 0.0001). Conclusions : Cannabis use is associated with a reduced risk of elevated fatty liver index in HIV-HCV co-infected patients. Further research is needed to confirm whether and how cannabinoids may inhibit the development of hepatic steatosis or other metabolic disorders in high-risk populations.
- Published
- 2021
- Full Text
- View/download PDF
48. Atherosclerotic Cardiovascular Events in Patients Infected With Human Immunodeficiency Virus and Hepatitis C Virus.
- Author
-
Tan BK, Chalouni M, Ceron DS, Cinaud A, Esterle L, Loko MA, Katlama C, Poizot-Martin I, Neau D, Chas J, Morlat P, Rosenthal E, Lacombe K, Naqvi A, Barange K, Bouchaud O, Gervais A, Lascoux-Combe C, Garipuy D, Alric L, Goujard C, Miailhes P, Aumaitre H, Duvivier C, Simon A, Lopez-Zaragoza JL, Zucman D, Raffi F, Lazaro E, Rey D, Piroth L, Boué F, Gilbert C, Bani-Sadr F, Dabis F, Sogni' P, Wittkop L, and Boccara F
- Subjects
- Adult, Female, HIV, Hepacivirus, Humans, Male, Middle Aged, Risk Factors, Cardiovascular Diseases epidemiology, Cardiovascular Diseases etiology, HIV Infections complications, HIV Infections epidemiology, Hepatitis C complications, Hepatitis C epidemiology
- Abstract
Background: An increased risk of cardiovascular disease (CVD) was reported in patients coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV), without identifying factors associated with atherosclerotic CVD (ASCVD) events., Methods: HIV-HCV coinfected patients were enrolled in the Agence Nationale de Recherches sur le Sida et les hépatites virales (ANRS) CO13 HEPAVIH nationwide cohort. Primary outcome was total ASCVD events. Secondary outcomes were coronary and/or cerebral ASCVD events, and peripheral artery disease (PAD) ASCVD events. Incidences were estimated using the Aalen-Johansen method. Factors associated with ASCVD were identified using cause-specific Cox proportional hazards models., Results: At baseline, median age of the study population (N = 1213) was 45.4 (interquartile range [IQR] 42.1-49.0) years and 70.3% were men. After a median follow-up of 5.1 (IQR 3.9-7.0) years, the incidence was 6.98 (95% confidence interval [CI], 5.19-9.38) per 1000 person-years for total ASCVD events, 4.01 (2.78-6.00) for coronary and/or cerebral events, and 3.17 (2.05-4.92) for PAD ASCVD events. Aging (hazard ratio [HR] 1.06; 95% CI, 1.01-1.12), prior CVD (HR 8.48; 95% CI, 3.14-22.91), high total cholesterol (HR 1.43; 95% CI, 1.11-1.83), high-density lipoprotein cholesterol (HR 0.22; 95% CI, 0.08-0.63), statin use (HR 3.31; 95% CI, 1.31-8.38), and high alcohol intake (HR 3.18; 95% CI, 1.35-7.52) were independently associated with total ASCVD events, whereas undetectable baseline viral load (HR 0.41, 95% CI, 0.18-0.96) was associated with coronary and/or cerebral events., Conclusions: HIV-HCV coinfected patients experienced a high incidence of ASCVD events. Some traditional cardiovascular risk factors were the main determinants of ASCVD. Controlling cholesterol abnormalities and maintaining undetectable HIV RNA are essential to control cardiovascular risk., (© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.)
- Published
- 2021
- Full Text
- View/download PDF
49. Exploring the risk of hypospadias in children born from mothers living close to a vineyard.
- Author
-
Bougnères P, Porcher R, Esterle L, Baker D, de la Vaissière A, Meurisse S, Valtat S, Castell AL, Mouriquand P, and Valleron AJ
- Subjects
- Case-Control Studies, Environmental Exposure, Female, France epidemiology, Humans, Hypospadias etiology, Hypospadias pathology, Male, Pregnancy, Risk Factors, Agriculture methods, Endocrine Disruptors adverse effects, Farms statistics & numerical data, Hypospadias epidemiology, Maternal Exposure adverse effects, Pesticides adverse effects, Prenatal Exposure Delayed Effects chemically induced
- Abstract
Hypospadias (H) is a common birth defect affecting the male urinary tract. It has been suggested that exposure to endocrine disrupting chemicals might increase the risk of H by altering urethral development. However, whether H risk is increased in places heavily exposed to agricultural pesticides, such as vineyards, remains debated and difficult to ascertain. The objective of the work is to test the possible association of H with residential proximity to vineyards. Residential address at birth of 8,766 H cases born 1980-2011 was taken from 17 specialized surgery centers. The geographical distribution of vineyards was obtained from the European Land Parcel Identification System (LPIS) and the distance of address to the nearest vineyard was computed. A first estimate of the variation of H relative risk with distance to vineyards was obtained using as controls 13,105 cryptorchidism (C) cases operated during the same period in the same centers. A separate estimate was obtained from a case-control study using "virtual controls" (VC) defined as points of the map sampled to match the demographic distribution of births within the recruitment territories of the study centers. Non-exposed patients were defined as those with a residence between 5,000 and 10,000 m from the closest vineyard. The residential distance to vineyard was smaller for H than for C cases (p<10-4). We found 42/8766 H cases (0.48%) and 50/13,105 C cases (0.38%) born to mothers living within 20 m of a vineyard. The odds ratios for H were 2.48 (CI: 1.0 to 5.1) and 2.4 (CI: 1.3 to 4.4), vs C or vs VC, respectively, when pregnant mothers lived 10-20 m from a vineyard. In conclusion, our study supports that children born to mothers living close to a vineyard have a two-fold increased risk of H. For environmental research, the use of VC provides an alternative to classical case control technique., Competing Interests: The authors have declared that no competing interests exist.
- Published
- 2021
- Full Text
- View/download PDF
50. Elevated Fatty Liver Index as a Risk Factor for All-Cause Mortality in Human Immunodeficiency Virus-Hepatitis C Virus-Coinfected Patients (ANRS CO13 HEPAVIH Cohort Study).
- Author
-
Barré T, Protopopescu C, Bani-Sadr F, Piroth L, Rojas Rojas T, Salmon-Ceron D, Wittkop L, Esterle L, Sogni P, Lacombe K, Chas J, Zaegel O, Chaix ML, Miailhes P, Serfaty L, Marcellin F, and Carrieri MP
- Subjects
- Antiviral Agents therapeutic use, Cause of Death, Cohort Studies, Coinfection drug therapy, Female, France epidemiology, HIV Infections drug therapy, Hepatitis C, Chronic drug therapy, Humans, Male, Middle Aged, Risk Factors, Coinfection mortality, Fatty Liver epidemiology, HIV Infections mortality, Hepatitis C, Chronic mortality
- Abstract
Background and Aims: Human immunodeficiency virus (HIV)-hepatitis C virus (HCV)-coinfected patients are at high risk of metabolic complications and liver-related events, which are both associated with hepatic steatosis and its progressive form, nonalcoholic steatohepatitis, a known risk factor for mortality. The fatty liver index (FLI), a noninvasive steatosis biomarker, has recently drawn attention for its clinical prognostic value, although its capacity to predict mortality risk in HIV-HCV-coinfected patients has never been investigated. Using a Cox proportional hazards model for mortality from all causes, with data from the French National Agency for Research on Aids and Viral Hepatitis CO13 HEPAVIH cohort (983 patients, 4,432 visits), we tested whether elevated FLI (≥60) was associated with all-cause mortality., Approach and Results: After multiple adjustment, individuals with FLI ≥ 60 had almost double the risk of all-cause mortality (adjusted hazard ratio [95% confidence interval], 1.91 [1.17-3.12], P = 0.009), independently of the following factors: HCV cure (0.21 [0.07-0.61], P = 0.004), advanced fibrosis (1.77 [1.00-3.14], P = 0.05), history of hepatocellular carcinoma and/or liver transplantation (7.74 [3.82-15.69], P < 10
-3 ), history of indirect clinical signs of cirrhosis (2.80 [1.22-6.41], P = 0.015), and HIV Centers for Disease Control and Prevention clinical stage C (2.88 [1.74-4.79], P < 10-3 )., Conclusions: An elevated FLI (≥60) is a risk factor for all-cause mortality in HIV-HCV-coinfected patients independently of liver fibrosis and HCV cure. In the present era of nearly 100% HCV cure rates thanks to direct-acting antivirals, these findings encourage the more systematic use of noninvasive steatosis biomarkers to help identify coinfected patients with higher mortality risk., (© 2019 by the American Association for the Study of Liver Diseases.)- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.